期刊文献+

来曲唑中残留溶剂四氯化碳顶空μ-ECD检测方法的建立和验证 被引量:1

Determination of Tetrachloromethane in Letrozol by Headspace Analysis with μ-ECD
原文传递
导出
摘要 目的建立用气相色谱外标法分析来曲唑中残留溶剂四氯化碳的方法。方法采用SE-30色谱柱,50℃~150℃程序升温,微电子捕获检测器检测。结果四氯化碳能与其他组分很好的分离,分离度(α)>2.0,且峰型对称。四氯化碳浓度在0.000 516~0.020 64μg.mL 1内,r=0.999 9,呈现良好的线性关系,检测限为0.01μg.g 1。采用的顶空进样的样品处理方法回收率高且对色谱柱及检测器的污染小。结论测定方法操作简便、快速、准确性高、重复性好,可作为本品的质量控制方法。 OBJECTIVE To establish a method for the quantitative determination of tetrachloromethane in Letrozol by GC.METHODS Tetrachloromethane was analyzed by Gas Chromatography with SE-30 column,μ-ECD detector,and programming temperature from 50 ℃ to 150 ℃.RESULTS Experimental results showed that a good separation of tetrachloromethane with other contents of sample was achieved on SE-30 column,and the separation degree was more than 2.0.The calibration curves of solvent was linear in 0.000 516 0.020 64 μg.mL 1.The limit of detection was 0.01 μg.g 1.CONCLUSION This method is simple,rapid,accurate and precise,and can be used for the quality control of residual tetrachloromethane in Letrozol.
出处 《中国现代应用药学》 CAS CSCD 2012年第9期843-845,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 气相色谱法 四氯化碳 微电子捕获检测器 来曲唑 gas chromatography tetrachloromethane μ-ECD Letrozol
  • 相关文献

参考文献3

二级参考文献16

  • 1马特,李爽,张强,赵林,龙飞,张斌.绝经后乳腺癌新辅助内分泌治疗近期疗效观察[J].中国肿瘤临床,2007,34(12):706-708. 被引量:10
  • 2TUBIANA-HULIN M, GARDNER M. Adjuvant chemotherapy [J]. Cancer Treat Res, 2009, 151: 121-137.
  • 3DUTTA U, PANT K. Aromatase inhibitors: past, present and future in breast cancer therapy [J]. Med Oncol, 2008, 25(2): 113-124.
  • 4OLSON J A JR, BUDD G T, CAREY L A, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial [J]. J Am Coil Surg, 2009, 208(5): 906-914.
  • 5SEMIGLAZOV V F, SEMIGLAZOV V V, DASHYAN G A, et al. Randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer [J]. Cancer, 2007, 110f2): 244-254.
  • 6ELLIS M J, MAC. Letrozole in the neoadjuvant setting: the P024 trial [J]. Breast Cancer Res Treat, 2007, 105(Suppl 1): 33-43.
  • 7WANGYX ZHANGAL ZHANGR etal.Neoadjuvant endocrine therapy using letrozole versus tamoxifen for postmenopausal breast cancer .南方医科大学学报,2008,28(4):667-668.
  • 8KRAINICK-STROBEL U E, LICHTENEGGER W, WALLWIENER D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase lib/Ill trial to investigate optimal duration of preoperative endocrine therapy [J]. BMC Cancer, 2008, 8: 62.
  • 9DIXON J M, RENSHAW L, MACASKILL E J, et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole [J]. Breast Cancer Res Treat, 2009, 113(1): 145-151.
  • 10ZHANGB ZHANGQ.Neoadjuvant systemic treatment for operable breast cancer .中华肿瘤杂志,2007,29(3):161-165.

共引文献9

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部